AROS-29 CRISPR/Cas9 KO Plasmid (h): sc-412385
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- AROS-29 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the AROS-29 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AROS-29 CRISPR/Cas9 KO Plasmid (h) | sc-412385 | 20 µg | $397.00 |
Overview
TMEM161A encodes AROS-29, a multi-pass transmembrane protein that localizes to intracellular membranes and is thought to contribute to membrane organization and homeostatic signaling in epithelial and other somatic cell types. Although its molecular partners remain incompletely defined, TMEM161A has been linked to processes involving organelle integrity, cellular stress responses, and regulation of growth-related pathways that intersect with membrane trafficking and proteostasis. Expression and genetic association data have connected TMEM161A to traits affecting epithelial function and inflammatory susceptibility, supporting continued investigation of its role in tissue maintenance. Dissecting AROS-29 biology can help clarify how membrane-embedded regulators influence signaling fidelity and cell-state transitions relevant to complex disease mechanisms.
AROS-29 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TMEM161A gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the TMEM161A together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the TMEM161A open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish AROS-29 protein expression.
This CRISPR knockout system enables efficient generation of TMEM161A-deficient cell models for investigation of AROS-29 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting TMEM161A exon(s) critical for AROS-29 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple TMEM161A genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by AROS-29 CRISPR/Cas9 KO Plasmid (h) and AROS-29 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the TMEM161A locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by AROS-29 HDR Plasmid (h) and AROS-29 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by TMEM161A homology arms to support homology-directed repair at defined TMEM161A target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.